[BTLA及其配体HVEM在慢性粒单核细胞白血病患者中的表达及意义]

[Expression and Significance of BTLA and Its Ligand HVEM in Patients with Chronic Myelomonocytic Leukemia].

作者信息

Li Chao, Geng Su-Xia, Li Min-Ming, Su Fang, Chen Xiao-Mei, Deng Cheng-Xin, Huang Xin, Lai Pei-Long, Weng Jian-Yu, DU Xin

机构信息

School of Medicine, South China University of Technology, Guangzhou 510006, Guangdong Province, China,Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China.

Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong Province, China.

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Feb;28(1):56-62. doi: 10.19746/j.cnki.issn.1009-2137.2020.01.010.

DOI:10.19746/j.cnki.issn.1009-2137.2020.01.010

PMID:32027253

Abstract

OBJECTIVE

To investigate the expression and significance of B and T lymphocyte weakening factor (BTLA) in patients with chronic myelomonocytic leukemia (CMML).

METHODS

Real-time PCR was used to detect the expression of BTLA and its ligand HVEM mRNA in 11 patients with chronic myelomonocytic leukemia and 11 normal donors. Flow cytometry was used to detect expression of BTLA and its HVEM on the cell surface of peripheral blood T lymphocytes and γδ T cells.

RESULTS

The median values of BTLA and its ligand HVEM mRNA expression in peripheral blood of patients with CMML were 0.009% and 559.4%, respectively, which were significantly lower than those of normal controls (0.053% and 1031%)(P<0.001). The expression level of BTLA and HVEM on cell surface of peripheral lymphocytes was not significantly different from that in normal controls (P=0.3031 and 0.2576), however, the proportion of peripheral blood T lymphocytes in patients with CMML (median: 37.73%) was significantly lower than that in controls (median 69.23%)(P=0.0005). The expression of BTLA on the surface of γδ T cells in peripheral blood of patients with CMML (median: 23.26%) was significantly lower than that of the controls (median: 52.64%) (P<0.05), and there was no significant abnormality in HVEM expression (P=0.2791).

CONCLUSION

The expression of BTLA and its ligand HVEM, the proportion of T lymphocytes and the expression of BTLA on the surface of γδ T cells in patients with CMML are reduced. The effects of these abnormalities on T cell function and prognosis and efficacy of patients need to be further observed.

摘要

目的

探讨B和T淋巴细胞弱化因子（BTLA）在慢性粒单核细胞白血病（CMML）患者中的表达及意义。

方法

采用实时荧光定量PCR检测11例慢性粒单核细胞白血病患者及11例正常供者外周血中BTLA及其配体HVEM mRNA的表达。采用流式细胞术检测外周血T淋巴细胞和γδT细胞表面BTLA及其HVEM的表达。

结果

CMML患者外周血中BTLA及其配体HVEM mRNA表达的中位数分别为0.009%和559.4%，显著低于正常对照组（0.053%和1031%）（P<0.001）。外周淋巴细胞表面BTLA和HVEM的表达水平与正常对照组相比无显著差异（P=0.3031和0.2576），然而，CMML患者外周血T淋巴细胞比例（中位数：37.73%）显著低于对照组（中位数69.23%）（P=0.0005）。CMML患者外周血γδT细胞表面BTLA的表达（中位数：23.26%）显著低于对照组（中位数：52.64%）（P<0.05），HVEM表达无显著异常（P=0.2791）。